People · Operator
Named in public records as an officer, director or promoter · active 2013–2018 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ammonett Pharma LLC | — | Pharmaceuticals | Seed | $2.4M | $90.7M | 2018 |
| Direct Spinal Therapeutics, Inc. | — | Biotechnology | Pre-Seed | $1.0M | $55.2M | 2013 |
| Acumen Pharmaceuticals, Inc. | — | Biotechnology | Pre-Seed | $700K | $38.6M | 2013 |
Daniel J. O'Connell at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel J. O'Connell on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Franz Hefti | 1 | 6 |
| Mark Lampert | 1 | 3 |
| Kevin P. Tully | 1 | 2 |
| Matthew A. Howard, M.D. | 1 | 1 |
| Grant Krafft | 1 | 1 |
| Jurgen W. Weber | 1 | 1 |
| William F. Goure | 1 | 1 |
| David W. Summa | 1 | 1 |
| Michael O. Thorner | 1 | 1 |
| John O. Brooks | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.